When Does Stelara's Patent Expire?
The primary patents for Stelara (ustekinumab) are set to expire in the United States in September 2023 [1]. However, the exact date of exclusivity loss can be influenced by factors such as patent challenges and other legal proceedings [2].
What Are the Key Patents for Stelara?
Stelara's core patent protection covers its active ingredient, ustekinumab, a human monoclonal antibody used to treat autoimmune diseases [3]. Patents related to its formulation and method of use also contribute to its market exclusivity [4]. DrugPatentWatch.com provides detailed information on these patents, including their expiration dates and status [1].
Are There Any Legal Challenges Affecting Stelara's Patent Exclusivity?
Yes, patent litigation is common for high-value biologic drugs like Stelara. Companies often challenge existing patents to pave the way for biosimilar entry. The outcome of these challenges can accelerate or delay the availability of generic alternatives [2].
When Can Biosimilar Versions of Stelara Enter the Market?
The earliest biosimilar versions of Stelara could become available in the U.S. after the primary patent expires in September 2023, assuming no further patent extensions or successful legal interventions by the innovator company [1][2]. The introduction of biosimilars typically follows patent expiry, although regulatory approval processes for biosimilars are separate and can take additional time [5].
How Does Stelara's Patent Expiry Affect Drug Pricing?
The expiration of patents and the subsequent introduction of biosimilar competitors generally lead to a decrease in drug prices. This increased competition offers more affordable treatment options for patients and healthcare systems [5].
What Are the Main Uses for Stelara?
Stelara is approved for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn's disease [3]. It is also used for ulcerative colitis [6].